ARTICLE | Preclinical News
New protein complex sensitizes cancers to PARP inhibitors
April 17, 2018 4:43 PM UTC
Researchers at University of Copenhagen and colleagues used a network-based proteomics approach to identify shieldin, a protein complex that sensitizes BRCA1-deficient cancers to PARP inhibitors, suggesting that shieldin component levels could guide precision medicine strategies.
In a paper published in Cell, the team used a biotin labeling- and mass spectrometry-based method to generate spatially resolved network maps of DNA repair proteins involved in DNA damage response pathways...
BCIQ Company Profiles